Purchase Order 36C24226P0417
Award Date 2/24/26
Potential Completion Date 3/24/26
Potential Value $39K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not listed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5) awarded a firm fixed-price purchase order to Theracom, L.L.C. for $38,097.52 for the supply of TAKHZYRO 150 MG, a specialized biologic pharmaceutical therapy. The contract was awarded on March 2, 2026, with an ultimate completion date of March 4, 2026, and no set-aside designation was utilized. Theracom, headquartered in Shepherdsville, Kentucky and operating from its Brooks, Kentucky facility, is a specialized...
- Theracom, L.L.C., a child entity, was awarded a firm fixed-price purchase order by Veterans Integrated Service Network 2 on October 20, 2025, for the supply of TAKHZYRO (pegtanercept) 150MG/ML injection in a 2ML syringe formulation. This is a pharmaceutical supply contract with a ceiling value of approximately $37.7K, with an ultimate completion date of November 20, 2025. The contract was awarded without a set-aside designation, and the place of performance is listed as Brooks, Kentucky. This...
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for LANADELUMAB-FLYO 150MG/ML INJ, SYRINGE,2ML (TAKHZYRO). The $221,342.40 firm fixed-price contract is issued against Takeda's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule. This specialized pharmaceutical product is used to treat hereditary angioedema, a rare and...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed-price delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for the supply of LANADELUMAB-FLYO (TAKHZYRO) 15OMG/ML INJ, SYRINGE, 2ML. This contract has a potential value of $110,671.20 and a completion date of June 6, 2024. The contract was issued against Takeda's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule....
- <p>This federal contract award is for the procurement of TAKHYZRO medication for patient use. The contract was awarded to Theracom, L.L.C., a for-profit limited liability company, on September 10, 2025. The contract has a firm fixed price of $37,739.06 and a completion date of October 31, 2025. The funding agency is the Veterans Integrated Service Network 2, a civilian agency. The contract does not have a set-aside designation.</p>
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order against the company's GSA Schedule contract for Pharmaceuticals and Drugs. The delivery order is for TAKHZYRO 150MG/ML SYRINGE 2ML SYRINGE (2) to be supplied to Veterans Integrated Service Network 9, with performance taking place in Lexington, Massachusetts from September 6-7, 2023. As the prime contractor, Takeda Pharmaceuticals America...
- This federal contract award, valued at $32,448.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a specialty medication, with a completion date of April 30, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running...
- The Defense Logistics Agency awarded a $34,342.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Takhzyro 300 mg/2 ml syringes on April 25, 2025, with completion required by May 16, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively granted with no set-aside designation, and...